Long-Acting Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Children

Summary A global phase 3 study evaluated the pharmacokinetics, efficacy and safety of a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in 27 previously treated male children (1–11 years) with severe and moderately severe haemophilia B (factor IX [FIX] activity ≤2 IU/dl). All patients received routine prophylaxis once every seven days for up to 77 weeks, and treated any bleeding episodes on-demand. The mean terminal half-life of rIX-FP was 91.4 hours (h), 4.3-fold longer than previous FIX treatment and clearance was 1.11 ml/h/kg, 6.4-fold slower than previous FIX treatment. The median (Q1, Q3) annualised spontaneous bleeding rate was 0.00 (0.00, 0.91) and was similar between the <6 years and ≥6 years age groups, with a weekly median prophylactic dose of 46 IU/kg. In addition, patients maintained a median trough level of 13.4 IU/dl FIX activity on weekly prophylaxis. Overall, 97.2% of bleeding episodes were successfully treated with one or two injections of rIX-FP (95% CI: 92% to 99%), 88.7% with one injection, and 96% of the treatments were rated effective (excellent or good) by the Investigator. No patient developed FIX inhibitors and no safety concerns were identified. These results indicate that rIX-FP is safe and effective for preventing and treating bleeding episodes in children with haemophilia B with weekly prophylaxis. Routine prophylaxis with rIX-FP at treatment intervals of up to 14 days are currently being investigated in children with severe and moderately severe haemophilia B. Clinicaltrials.gov (NCT01662531)

[1]  E. Santagostino,et al.  Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. , 2016, Blood.

[2]  E. Santagostino,et al.  Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  J. Oldenburg,et al.  Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. , 2014, Blood.

[4]  R. Ljung,et al.  Definitions in hemophilia: communication from the SSC of the ISTH , 2014, Journal of thrombosis and haemostasis : JTH.

[5]  O. Stasyshyn,et al.  Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open‐label, uncontrolled, multicentre, phase III study , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  S. Perkins,et al.  An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B , 2013, Journal of thrombosis and haemostasis : JTH.

[7]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  P. Monagle,et al.  Association between physical activity and risk of bleeding in children with hemophilia. , 2012, JAMA.

[9]  M. Morfini,et al.  Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. , 2012, Blood.

[10]  A. Mäkipernaa,et al.  MRI after removal of central venous access device reveals a high number of asymptomatic thromboses in children with haemophilia , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  P. Reitsma,et al.  Nomenclature of genetic variants in hemostasis , 2011, Journal of thrombosis and haemostasis : JTH.

[12]  E. Santagostino,et al.  Venous access in haemophilic children: choice and management , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  A. Daneman,et al.  A prospective, longitudinal study of central venous catheter‐related deep venous thrombosis in boys with hemophilia , 2004, Journal of thrombosis and haemostasis : JTH.

[14]  K. Pasi,et al.  Haemophilias A and B , 2003, The Lancet.

[15]  C. Kessler,et al.  Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. , 2001, Blood.

[16]  C. Quinn,et al.  Catheter-related deep venous thrombosis in children with hemophilia. , 2001, Blood.

[17]  M. Morfini,et al.  The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors , 2001 .

[18]  M. van den Berg,et al.  The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability , 1995, Thrombosis and Haemostasis.

[19]  M. Morfini,et al.  The Design and Analysis of Half-Life and Recovery Studies for Factor VIII and Factor IX , 1991, Thrombosis and Haemostasis.